Matt Egan
CNN.com
Originally posted June 19, 2018
A top Wells Fargo (WFC) executive said on Tuesday that employees are increasingly using the bank's confidential hotline to report bad behavior.
"Our volumes increased on our ethics line. We're glad they did. People raised their hand," said Theresa LaPlaca, who leads a conduct office that Wells Fargo created last year.
"That is success for me," LaPlaca said at the ACFE Global Fraud Conference in Las Vegas.
Reassuring Wells Fargo workers to trust the bank's ethics hotline is no easy task. Nearly half a dozen workers told CNNMoney in 2016 that they were fired by Wells Fargo after calling the hotline to try to stop the bank's fake-account problem.
Last year, Wells Fargo was ordered to re-hire and pay $5.4 million to a whistleblower who was fired after calling the ethics hotline to report suspected fraud. Wells Fargo faces multiple lawsuits from employees who say they protested sales misconduct. The bank said in a filing that it also faces state law whistleblower actions filed with the Labor Department alleging retaliation.
The information is here.
Showing posts with label Consumer Fraud. Show all posts
Showing posts with label Consumer Fraud. Show all posts
Thursday, June 21, 2018
Wednesday, November 26, 2014
Ethical Responsibilities of Direct-to-Consumer Neuroscience Companies
By Mary Darby
blog.bioethics.gov
Published on November 5, 2014
As part of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, President Obama asked the Presidential Commission for the Study of Bioethical Issues (Bioethics Commission) to “identify proactively a set of core ethical standards – both to guide neuroscience research and to address some of the ethical dilemmas that may be raised by the application of neuroscience research findings.”
This morning, the Bioethics Commission resumed its consideration of ethical issues related to direct-to-consumer (DTC) neuroscience, including products like dietary supplements, neurofeedback devices, and even memory games.
The entire blog post is here.
blog.bioethics.gov
Published on November 5, 2014
As part of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, President Obama asked the Presidential Commission for the Study of Bioethical Issues (Bioethics Commission) to “identify proactively a set of core ethical standards – both to guide neuroscience research and to address some of the ethical dilemmas that may be raised by the application of neuroscience research findings.”
This morning, the Bioethics Commission resumed its consideration of ethical issues related to direct-to-consumer (DTC) neuroscience, including products like dietary supplements, neurofeedback devices, and even memory games.
The entire blog post is here.
Tuesday, November 27, 2012
L.A. Psych School Lied, Class Claims
By WILLIAM DOTINGA
Courthouse News Service
November 15, 2012
Students claim in a class action that the Los Angeles campus of the Chicago School of Professional Psychology recruited them by lying that it was accredited by the American Psychological Association.
Miranda Jo Truitt and three other named plaintiffs sued the Chicago School of Professional Psychology and its subsidiaries, including TCS Global, in Superior Court. They allege fraud, conspiracy, false advertising and consumer law violations.
Also named as defendants are the California Graduate Institute and the school's national president Michelle Nealon-Woods and "lead faculty" member of the Los Angeles campus, David Sitzer.
The students claim the Chicago School of Professional Psychology, or TCS, was "ostensibly formed, organized and operated exclusively for exempt purposes under section 501(c)(3) of the Internal Revenue Code for the 'advancement of education and science,' but in fact is being operated by its management team for the benefit of private interests for financial profit and personal gain through a network of interrelated companies and entities owned and controlled by TCS.
The entire story is here.
Thanks to Ken Pope for this story.
Courthouse News Service
November 15, 2012
Students claim in a class action that the Los Angeles campus of the Chicago School of Professional Psychology recruited them by lying that it was accredited by the American Psychological Association.
Miranda Jo Truitt and three other named plaintiffs sued the Chicago School of Professional Psychology and its subsidiaries, including TCS Global, in Superior Court. They allege fraud, conspiracy, false advertising and consumer law violations.
Also named as defendants are the California Graduate Institute and the school's national president Michelle Nealon-Woods and "lead faculty" member of the Los Angeles campus, David Sitzer.
The students claim the Chicago School of Professional Psychology, or TCS, was "ostensibly formed, organized and operated exclusively for exempt purposes under section 501(c)(3) of the Internal Revenue Code for the 'advancement of education and science,' but in fact is being operated by its management team for the benefit of private interests for financial profit and personal gain through a network of interrelated companies and entities owned and controlled by TCS.
The entire story is here.
Thanks to Ken Pope for this story.
Sunday, September 9, 2012
Johnson & Johnson Unit Settles State Cases Over Risperdal
By Katie Thomas
The New York Times - Business Day
Originally published August 30, 2012
The New York Times - Business Day
Originally published August 30, 2012
Johnson & Johnson announced Thursday that its pharmaceutical unit had reached a $181 million consumer fraud settlement with 36 states and the District of Columbia over its marketing of Risperdal, an antipsychotic drug.
The company’s pharmaceuticals subsidiary, Janssen, has been under scrutiny for years over its promotion of Risperdal, which treats symptoms of bipolar mania and schizophrenia. State and federal authorities have said that Janssen promoted the drug for uses it did not have approval for, including dementia in elderly patients, bipolar disorder in children and adolescents, depression and anxiety. Prosecutors have also accused the company of minimizing or concealing the risks associated with the drug.
In resolving the allegations by the states, Janssen did not admit wrongdoing or that it violated the law and said it settled to avoid “unnecessary expense and a prolonged legal process.”
Subscribe to:
Posts (Atom)